BeiGene Ltd Ordinary Shares 06160
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
BeiGene Provides Update on FDA Advisory Committee Vote on Benefit-Risk Profile of PD-1 Inhibitors, including TEVIMBRA®, for Treatment of ESCC and Gastric/GEJ Cancers
-
Global Oncology Innovator BeiGene Appoints Shalini Sharp to Board of Directors
-
BeiGene Announces Updates to Commercial Leadership Team
-
BeiGene to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
-
BeiGene’s BGB-16673 Receives U.S. FDA Fast Track Designation for CLL/SLL
-
BeiGene Enters Next Phase of Global Growth with Announcement of Second Quarter 2024 Financial Results and Corporate Updates
-
BeiGene Opens Flagship U.S. Biologics Manufacturing and Clinical R&D Facility, Continues Global Expansion to Deliver Medicines to More Patients Around the World
-
BeiGene Announces Appointment of Aaron Rosenberg as Chief Financial Officer
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 7.51
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
BeiGene Ltd is a global oncology company that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. BeiGene’s key cancer treatments are BRUKINSA (zanubrutinib), Bruton's tyrosine kinase (BTK) inhibitor, and TEVIMBRA (tislelizumab), an anti-PD-1 antibody. In addition, it has a diverse pipeline of novel therapeutics focusing on a range of malignancies, including AML, MDS, multiple myeloma, lung, gastrointestinal, breast, and gynecologic cancers. The Company operates in one segment: pharmaceutical products and is primarily located in the U.S. and the PRC. Key revenue is generated from the U.S.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Large Growth
- Total Number of Employees
- 9,000
- Website
- https://www.beigene.com
Comparables
Valuation
|
Metric
|
06160
|
09688
|
6550
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 7.01 | 3.22 | 5.94 |
Price/Sales | 7.51 | 6.94 | 625.56 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
06160
|
09688
|
6550
|
|---|---|---|---|
Quick Ratio | 1.64 | 2.81 | 9.39 |
Current Ratio | 1.98 | 3.46 | 9.86 |
Interest Coverage | — | — | −41.75 |
Quick Ratio
06160
09688
6550
Profitability
|
Metric
|
06160
|
09688
|
6550
|
|---|---|---|---|
Return on Assets (Normalized) | −2.03% | −22.08% | −18.61% |
Return on Equity (Normalized) | −3.24% | −27.96% | −22.52% |
Return on Invested Capital (Normalized) | −4.24% | −31.10% | −21.09% |
Return on Assets
06160
09688
6550
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Kvwysdllhr | Zqzt | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Shrlvbt | Jzqkyc | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Tkpbhpb | Pdylb | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Msvbgnd | Fbrzsq | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Yckpjftq | Xymm | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Dvmswqdk | Rzxh | $28.1 Bil | |||
| Moderna Inc
MRNA
| Nxxnrltp | Ntn | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Cflqqhmqm | Xnktg | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Pfbhvzbx | Yzgkkr | $13.4 Bil | |||
| Incyte Corp
INCY
| Qtvwwzd | Cmjkwm | $12.7 Bil |
United States